Recent developments for NEXGEL include leadership changes with a new CFO appointment, earnings releases for Q1 2026 and Q3 2025, expansion of partnerships, and licensing agreements for biomaterial products.

• NEXGEL released its Q1 2026 earnings transcript detailing recent financial and operational updates [N1].
• Ian Blackman was named Chief Financial Officer in April 2026, bringing over 30 years of financial leadership experience [N2][N3].
• The company expanded its partnership with STADA Arzneimittel AG to launch new health solutions in mid-2025 [N7].
• NEXGEL signed an agreement with Celularity to license and acquire six biomaterial products, enhancing its regenerative medicine portfolio [N4].
• The company reported significant revenue growth in fiscal Q2 2025, with revenue doubling compared to prior periods [N6].
• NEXGEL announced plans to release first quarter 2025 financial results and host a conference call in May 2025 [N8].

NEXGEL has demonstrated strong revenue growth in recent years, including 181% growth in Q4 2024 and doubling revenue in fiscal Q2 2025, indicating market acceptance of its products [N6][N7]. The acquisition of Celularity’s regenerative biomaterials portfolio provides a commercial-stage product base with potential for further expansion. The company’s leadership team and board bring significant experience in finance, biotech, and capital markets, supporting strategic growth initiatives. Recent partnerships and licensing agreements may enhance product offerings and market reach. The appointment of a seasoned CFO in 2026 may strengthen financial management and capital strategy [N2][N3].

NEXGEL reported a net loss of $3.635 million and negative EPS of $0.40 for Q2 2026, with liquidity ratios indicating current liabilities significantly exceed current assets, reflecting potential liquidity constraints [S2]. The company has substantial convertible notes payable totaling $14.7 million with high interest rates and dilution risk, which could adversely affect financial flexibility and shareholder value [S2]. The integration and commercialization of the licensed biomaterials portfolio from Celularity may require significant management attention and expenditures, with uncertain realization of anticipated benefits [S2]. The competitive and regulatory environment in regenerative biomaterials presents execution risks. The company’s financial condition and ongoing losses highlight operational and funding challenges.

NEXGEL’s moat is primarily based on its exclusive license to Celularity’s commercial-stage regenerative biomaterials portfolio, which provides proprietary product offerings under the BioNx brand. The company’s partnerships and licensing agreements, such as with STADA Arzneimittel AG, support its market presence and product distribution. The expertise of its leadership team and board, with backgrounds in finance, biotech, and capital markets, supports strategic execution. However, the company operates in a competitive biotech and regenerative medicine sector where product development, regulatory approvals, and commercialization are critical and challenging. The moat is thus dependent on successful commercialization and integration of licensed products and maintaining competitive differentiation in the biomaterials market.

• Liquidity and Financial Risk: As of June 30, 2026, NEXGEL’s current liabilities exceed current assets with a current ratio of 0.43 and cash ratio of 0.11, indicating potential liquidity challenges [S2].
• Convertible Notes and Dilution Risk: The company has $14.7 million in convertible notes issued in 2026 bearing 10% interest, convertible into common stock with downward adjustment provisions, posing dilution risk to existing shareholders and potential financial strain [S2].
• Integration and Commercialization Risk: The acquisition of Celularity’s regenerative biomaterials portfolio may not achieve anticipated benefits and could require significant additional expenditures and management focus, impacting operational performance [S2].
• Operational Losses: NEXGEL reported a net loss of $3.635 million and negative EPS of $0.40 for Q2 2026, reflecting ongoing operational losses that may affect sustainability without improved financial performance [S2].
• Competitive and Regulatory Environment: The regenerative biomaterials sector is competitive and subject to regulatory approvals, which may impact product commercialization and market acceptance.

• NEXGEL, INC. is a publicly traded company on the Nasdaq Capital Market under the ticker NXGL and NXGLW for warrants [S1].
• The company is incorporated in Delaware and headquartered in Langhorne, Pennsylvania [S1].
• As of April 28, 2026, NEXGEL had 8,849,665 shares of common stock outstanding [S1].
• The company’s executive leadership includes Adam Levy as CEO and President, Ian Blackman as CFO (appointed April 27, 2026), and a board of directors with members having expertise in finance, biotech, and capital markets [S1].
• NEXGEL’s Audit Committee is composed of independent directors with financial expertise, including an audit committee financial expert [S1].
• The company completed an acquisition of an exclusive license to Celularity’s commercial-stage regenerative biomaterials portfolio in April 2026 for $13.3 million upfront, with potential contingent milestone payments up to $20 million [S2].
• NEXGEL’s financial snapshot as of June 30, 2026, shows cash and equivalents of $938,000, current assets of $6.17 million, current liabilities of $14.44 million, resulting in a current ratio of 0.43 and a cash ratio of 0.11 [S2].
• The company reported a net loss of $3.635 million and basic and diluted EPS of -$0.40 for the quarter ended June 30, 2026 [S2].
• NEXGEL has substantial convertible notes payable of $14.7 million issued in 2026 bearing 10% interest, convertible into common stock with potential dilution risk [S2].
• Recent business developments include a new CFO appointment, Q1 2026 earnings release, expansion of partnerships, and licensing agreements for biomaterial products [N1][N2][N3][N7].
• The company has reported significant revenue growth in prior periods, including 181% Q4 2024 and 112% full-year 2024 revenue growth, with revenue doubling in fiscal Q2 2025 [N6][N7].